Although not yet showing up in our numbers, we see early but encouraging signs of improvement, including more customer visits in Germany during the quarter, continued strong positive support from customers, where the feedback on lower orders in Germany have been primarily due to hospital challenges such as staffing shortages, budgets, ICU capacity, and lower numbers of severely ill patients, a significantly increased flow of positive data on cytosol across both critical care and cardiac surgery, greater in-person attendance of healthcare providers at conferences, and improved cross-functional synergy within our company based on our new therapy area vertical strategy and leadership.

Aug 2, 2022 / CEO / receipt, needs a key / Dr. Philip Chan, CEO | earnings call 2022-08-02 | transcript f199525d-4459-4320-bff4-28f0bf293ead | chars 5627-6317 | segment 5